

Form PTO-1449
(Rev. 8-83)
(modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
13726US01

SERIAL NO.
10/000,107

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)


APPLICANT(s):
Schoenhard

FILING DATE
October 30, 2001


GROUP ART UNIT
1645

RECEIVED
OCT 14 2003
TECH CENTER 1600/2900


U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,214,368	04/10/01	Lee	424	423	
	2001/006948	07/05/01	Kang et al.	514	44	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	PUBLICATIO N DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 02/098422 A1	12/2002	PCT				
	WO 03/037340 A1	05/2003	PCT				
	WO 01/85153 A2	11/2001	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Then, "Potentiation by EDTA and levallorphan of the effect of sulfamethoxazole-trimethoprim on Escherichia coli, Experientia. Switzerland vol. 28(9):1118-1119 (September 15, 1972)
	Gekker, et al., "Naltrexone potentiates anti-HIV-1 activity of antiretroviral drugs in CD4+ lymphocyte cultures" Drug and Alcohol Dependence 64(3):257-263 (November, 2001)
	Lovekamp, et al., Inhibition of Human Multidrug Resistance P-glycoprotein 1 by Analogues of a Potent Delta-Opioid Antagonist, 902:131-134 (2001)
	PCT International Search Report, Application No. PCT/US02/17153 dated 7/7/03

EXAMINER

DATE CONSIDERED:

*EXAMINER: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.